• [[ Whitepaper ]] Connecting With Rare Disease Patient Communities: Patient Advocates

    laureng Whitepapers April 19, 2018
  • [[Whitepaper ]] Disruptive Innovation in Rare Disease Markets

    laureng Whitepapers April 19, 2018
  • Choosing the Right Channel Strategy for Specialty Product Success

    Karina Kusova Clinical Development, Market Access, Orphan Drug Congress, Supply Chain & Manufacturing, Uncategorized, Whitepapers May 3, 2017
  • [Whitepaper] Challenging Conventional Patient Recruitment and Care Strategies for Rare Disease Studies

    Karina Kusova Clinical Development, Orphan Drug Congress, Uncategorized, Whitepapers April 10, 2017
  • [[whitepaper]] The New Reality: Maximizing Value in Rare Disease Launches

    Karina Kusova Clinical Development, Featured on App, Orphan Drug Congress, Uncategorized, Whitepapers April 6, 2017
  • What’s New in Rare Cancer Research? (Spoiler Alert: A Lot!)

    Karina Kusova Advocacy, Clinical Development, Market Access, Orphan Drug Congress, Orphan Drugs Live October 10, 2016

Subscribe to Total Orphan Drugs

Strategy and innovation in the orphan drugs and rare diseases industry
Navigation
  • Development
  • Regulation
  • Advocacy
  • Market Access
  • Partnering & Investment
  • Whitepapers
  • Events
    • USA
  • Search
bortezomib

Tag Archive

View Post

Janssen Submits EU Marketing Application for VELCADE® (bortezomib) in Mantle Cell Lymphoma

In Press Release by CameronJune 30, 2014Leave a Comment

Type II variation submitted to the European Medicines Agency to expand current VELCADE® label to include previously untreated patients with Mantle Cell Lymphoma June 27, 2014 …

View Post

VELCADE® Data at EHA 2014 Highlight Efficacy in Newly-Diagnosed Mantle Cell Lymphoma and Reinforce Its Role as a Backbone of Multiple Myeloma Therapy

In Press Release by CameronJune 16, 2014Leave a Comment

June 15, 2014 Janssen-Cilag International NV today announced Phase III study data demonstrating that the investigational use of a VELCADE® (bortezomib)-based combination in the treatment …

View Post

Phase 3 Data Highlight Benefits of Using VELCADE® within Frontline Treatment of Mantle Cell Lymphoma, with Results Showing Significantly Longer Progression-Free Survival Compared to Standard of Care

In Press Release by CameronJune 2, 2014Leave a Comment

Investigational study reports potential benefits of VELCADE (bortezomib)-based combination therapy when used as an initial treatment in this rare blood cancer June 1, 2014 Janssen-Cilag …

Categories

  • Advocacy
  • Clinical Development
  • Featured on App
  • Market Access
  • Orphan Drug Congress
  • Orphan Drugs Live
  • Partnering & Investment
  • Press Release
  • Regulation & Government
  • Reports
  • Supply Chain & Manufacturing
  • Uncategorized
  • Whitepapers
Toggle the Widgetbar
World Orphan Drug Congress USA
  • Home
  • About Us/Advertise